Selected article for: "clinical trial and SARS coronavirus"

Author: Meyers, Craig; Robison, Richard; Milici, Janice; Alam, Samina; Quillen, David; Goldenberg, David; Kass, Rena
Title: Rebuttal to Overinterpretation of the antiviral results for human coronavirus 229E (HCoV-229E) relative to severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) by Rowpar Pharmaceuticals.
  • Cord-id: 0nhs5vne
  • Document date: 2020_12_29
  • ID: 0nhs5vne
    Snippet: Recently, employees of Rowpar Pharmaceuticals Inc., wrote a commentary entitled, "Overinterpretation of the antiviral results for human coronavirus 229E (HCoV-229E) relative to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)." In their commentary they discussed our recent publication entitled, "Lower the transmission and spread of human coronavirus." In their commentary there is a limited discussion of accepted virucidal analysis, confusing virucidal assays with assays to determine
    Document: Recently, employees of Rowpar Pharmaceuticals Inc., wrote a commentary entitled, "Overinterpretation of the antiviral results for human coronavirus 229E (HCoV-229E) relative to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)." In their commentary they discussed our recent publication entitled, "Lower the transmission and spread of human coronavirus." In their commentary there is a limited discussion of accepted virucidal analysis, confusing virucidal assays with assays to determine mechanisms of infection. Also ignored is the corroboration of our studies by others using SARS-CoV-2, including a clinical trial. We will now address their comments, including providing the corroborative published studies. This article is protected by copyright. All rights reserved.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1
    Co phrase search for related documents, hyperlinks ordered by date